Oblique Therapeutics Welcomes Dr. Jan Lundberg as a Scientific Advisor

Oblique Therapeutics has proudly announced a key recruitment that could mark a turning point in the development of its pioneering drug platform focused on treating pain and inflammatory diseases. Dr. Jan Lundberg, a recognized name in both academia and the pharmaceutical industry, has accepted the role of Scientific Advisor. His extensive experience is expected to significantly bolster the company's capabilities in drug research and development.

Dr. Lundberg's career is nothing short of remarkable. He began his journey at the prestigious Karolinska Institute, where he established himself as one of the planet’s 100 most cited scientists early in his career. Following his academic tenure, he transitioned to the corporate world and made significant contributions to AstraZeneca, where he held prominent roles in research and development. His expertise caught the attention of Eli Lilly, where he served as Global Head of Research. Under his leadership, the company's research strategy flourished, firmly establishing Eli Lilly as a dominant player in the global pharmaceutical market.

Notably, Dr. Lundberg was instrumental in developing GLP-1-based medications, including ones that have gained considerable recognition in the treatment of obesity and metabolic diseases. Medicines such as Ozempic, developed during his tenure, are now essential in contemporary treatment protocols. Aside from his success in metabolic treatments, Dr. Lundberg played a crucial role in advancing therapies for conditions like Alzheimer's disease and migraine, which underscore his diverse capabilities in drug development.

A unique contributor to the pharmaceutical field, Dr. Lundberg was also a pioneer in creating antibody therapies specifically for migraine and cluster headaches—conditions that traditionally have been challenging to address.

At Oblique Therapeutics, the focus is on next-generation antibody-based therapeutics, particularly concerning TRPV1—an ion channel that plays a significant role in pain sensations. Dr. Lundberg's scientific acumen and rich experience in translational research will be invaluable assets as Oblique continues to innovate in pain management therapies. His extensive network within both the academic and industrial realms is expected to facilitate collaborations and accelerate the drug development pipeline.

In his own words, Dr. Lundberg expressed enthusiasm about joining Oblique Therapeutics, stating, "I have been involved in research surrounding capsaicin, TRPV1, and pain since the very earliest days. It is thrilling to witness the advancements that Oblique Therapeutics is making. The company’s focus on antibody-based treatments may provide a viable alternative to existing TRPV1 blockers, which have faced challenges due to systemic treatment side effects. The chance to work on potentially transformative therapies for patients suffering from chronic pain is both a scientific and personal inspiration for me."

Christer Nordstedt, CEO of Oblique Therapeutics, shared his excitement about Dr. Lundberg's engagement with the company. He remarked, "We are extremely pleased and proud that Dr. Jan Lundberg has chosen to engage with Oblique Therapeutics. His unparalleled scientific reputation, along with his proven ability to build successful pharmaceutical portfolios, represents a tremendous advantage for us as we move forward."

As Oblique Therapeutics embarks on this fresh chapter with Dr. Lundberg's guidance, the prospect of developing groundbreaking treatments for chronic pain promises to redefine the landscape of pain management and demonstrate the true potential of innovative therapeutic strategies.

The team's commitment to advancing medical science remains steadfast, fueled by the strategic vision that Dr. Lundberg brings to the table. With such a distinguished advisor paving the way, Oblique Therapeutics stands on the brink of substantial advancements in drug development that could one day improve countless lives.

Oblique Therapeutics is headquartered in Gothenburg, Sweden, where it continues to drive forward with ambitious aim and robust expertise. Stay tuned for further updates as the company progresses toward its promising future in the pharmaceutical industry.